Drug General Information
Drug ID	D0MR4Q
Former ID	DIB000458
Drug Name	CCX-168
Indication	Vasculitis [ICD10:I77.6, I80]		Phase 2	[525112]
Company	ChemoCentryx
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	C5aR	Target Info	Antagonist	[550548]
KEGG Pathway	Neuroactive ligand-receptor interaction
	Complement and coagulation cascades
	Staphylococcus aureus infection
PANTHER Pathway	Inflammation mediated by chemokine and cytokine signaling pathway
Reactome	Peptide ligand-binding receptors
	G alpha (i) signalling events
WikiPathways	Complement and Coagulation Cascades
	Human Complement System
	Peptide GPCRs
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 525112	ClinicalTrials.gov (NCT02384317) Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade. U.S. National Institutes of Health.
Ref 550548	Clinical pipeline report, company report or official report of ChemoCentryx.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.